Micah Breiger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Micah Breiger has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Diego A. Pizzagalli
Noel Drury, M.D. Institute for Translational Depression Discoveries, University of California, Irvine, USA
2 shared publications - Hans S. Schroder
University of Michigan Medical School
2 shared publications Andre Der-Avakian
University of California San Diego
1 shared publication- Ann M. Iturra-Mena
Department of Psychiatry, Columbia University, New York, NY, 10032, USA; Data Science Institute, Columbia University, New York, NY, 10027, USA
1 shared publication - Brian D. Kangas
Department of Psychiatry, Harvard Medical School & McLean Hospital, Belmont, USA
1 shared publication David Breiger
Department of Psychiatry and Behavioral Medicine, Seattle Children’s Hospital and Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, Washington
1 shared publication
Latest Publications
- 31 March 2022
- Published by MIT Press in Journal of Cognitive Neuroscience
- Vol. 34 (5) , 864-876
Error-related Alpha Suppression: Scalp Topography and (Lack of) Modulation by Modafinil
Errors in performance trigger cognitive and neural changes that are implemented to adaptively adjust to fluctuating demands. Error-related alpha suppression (ERAS)—which refers to decreased power in the alpha frequency band after an incorrect response—is thought to reflect cognitive arousal after errors. Much of this work has been correlational, however, and there are no direct investigations into its pharmacological sensitivity. In Study 1 (n = 61), we evaluated the presence and scalp distribution of ERAS in a novel flanker task specifically developed for cross-species assessments. Using this same task in Study 2 (n = 26), which had a placebo-controlled within-subject design, we evaluated the sensitivity of ERAS to placebo (0 mg), low (100 mg), and high (200 mg) doses of modafinil, a wakefulness promoting agent. Consistent with previous work, ERAS was maximal at parieto-occipital recording sites in both studies. In Study 2, modafinil did not have strong effects on ERAS (a significant Accuracy × Dose interaction emerged, but drug–placebo differences did not reach statistical significance after correction for multiple comparisons and was absent after controlling for accuracy rate). ERAS was correlated with accuracy rates in both studies. Thus, modafinil did not impact ERAS as hypothesized, and findings indicate ERAS may reflect an orienting response to infrequent events.
- 31 March 2022
- Published by MIT Press in Journal of Cognitive Neuroscience
- Vol. 34 (5) , 864-876
Error-related Alpha Suppression: Scalp Topography and (Lack of) Modulation by Modafinil
Errors in performance trigger cognitive and neural changes that are implemented to adaptively adjust to fluctuating demands. Error-related alpha suppression (ERAS)—which refers to decreased power in the alpha frequency band after an incorrect response—is thought to reflect cognitive arousal after errors. Much of this work has been correlational, however, and there are no direct investigations into its pharmacological sensitivity. In Study 1 (n = 61), we evaluated the presence and scalp distribution of ERAS in a novel flanker task specifically developed for cross-species assessments. Using this same task in Study 2 (n = 26), which had a placebo-controlled within-subject design, we evaluated the sensitivity of ERAS to placebo (0 mg), low (100 mg), and high (200 mg) doses of modafinil, a wakefulness promoting agent. Consistent with previous work, ERAS was maximal at parieto-occipital recording sites in both studies. In Study 2, modafinil did not have strong effects on ERAS (a significant Accuracy × Dose interaction emerged, but drug–placebo differences did not reach statistical significance after correction for multiple comparisons and was absent after controlling for accuracy rate). ERAS was correlated with accuracy rates in both studies. Thus, modafinil did not impact ERAS as hypothesized, and findings indicate ERAS may reflect an orienting response to infrequent events.
- 19 September 2019
- Published by Wiley in Psychophysiology
- Vol. 57 (2) , e13473
Optimizing assessments of post‐error slowing: A neurobehavioral investigation of a flanker task
Appropriately adjusting to errors is essential for adaptive behavior. Post‐error slowing (PES) refers to the increased reaction times on trials following incorrect relative to correct responses. PES has been used as a metric of cognitive control in basic cognitive neuroscience research as well as clinical contexts. However, calculation of PES varies widely among studies and has not yet been standardized, despite recent calls to optimize its measurement. Here, using behavioral and electrophysiological data from a modified flanker task, we considered different methods of calculating PES, assessed their internal consistency, examined their convergent correlations with behavioral performance and error‐related event‐related brain potentials (ERPs), and evaluated their sensitivity to task demands (e.g., presence of trial‐to‐trial feedback). Results indicated that the so‐called robust measure of PES, calculated using only error‐surrounding trials, provided an estimate of PES that was three times larger in magnitude than the traditional calculation. This robust PES correlated with the amplitude of the error positivity (Pe), an index of attention allocation to errors, just as well as the traditional method. However, all PES estimates had very weak internal consistency. Implications for measurement are discussed.
- 19 September 2019
- Published by Wiley in Psychophysiology
- Vol. 57 (2) , e13473
Optimizing assessments of post‐error slowing: A neurobehavioral investigation of a flanker task
Appropriately adjusting to errors is essential for adaptive behavior. Post‐error slowing (PES) refers to the increased reaction times on trials following incorrect relative to correct responses. PES has been used as a metric of cognitive control in basic cognitive neuroscience research as well as clinical contexts. However, calculation of PES varies widely among studies and has not yet been standardized, despite recent calls to optimize its measurement. Here, using behavioral and electrophysiological data from a modified flanker task, we considered different methods of calculating PES, assessed their internal consistency, examined their convergent correlations with behavioral performance and error‐related event‐related brain potentials (ERPs), and evaluated their sensitivity to task demands (e.g., presence of trial‐to‐trial feedback). Results indicated that the so‐called robust measure of PES, calculated using only error‐surrounding trials, provided an estimate of PES that was three times larger in magnitude than the traditional calculation. This robust PES correlated with the amplitude of the error positivity (Pe), an index of attention allocation to errors, just as well as the traditional method. However, all PES estimates had very weak internal consistency. Implications for measurement are discussed.
- Open Access
- 23 May 2019
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 21 (10) , 1310-1318
Differential trajectories of neurocognitive functioning in females versus males following treatment for pediatric brain tumors
Female and male trajectories of cerebellar and lobar brain structures are sexually dimorphic, making sex a potential candidate moderator of neurocognitive late effects from radiation treatment. We sought to evaluate longitudinal neurocognitive functioning in male versus female children treated for posterior fossa brain tumors. Fifty-one female and 63 male survivors of posterior fossa tumors completed neuropsychological testing at 2 timepoints. We included patients treated with surgical resection, chemotherapy, and radiation therapy. Multilevel mixed modeling was used to predict IQ score as a function of patient sex following treatment (~2 or ~4 years post treatment). Effect sizes were used as a measure of clinical significance. Multilevel models resulted in a significant sex by time interaction (F = 6.69, P = 0.011). Females’ cognitive scores were considerably higher compared with males at 4 years posttreatment. Females demonstrated an average improvement of 7.61 standard score IQ points compared with a decline of 2.97 points for males at 4 years follow-up. Effect sizes for female IQ compared with male IQ at 4 years posttreatment were between 0.8 and 0.9. Trajectories of neurocognitive functioning following posterior fossa tumor treatment differed between female and male children. Sexual dimorphism in radiation late effects may alter treatment decisions in children. Research into sex-specific neuroprotective mechanisms underlying neurocognitive development following pediatric brain tumor treatments is warranted.
- 23 May 2019
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 21 (10) , 1310-1318
Open AccessDifferential trajectories of neurocognitive functioning in females versus males following treatment for pediatric brain tumors
Female and male trajectories of cerebellar and lobar brain structures are sexually dimorphic, making sex a potential candidate moderator of neurocognitive late effects from radiation treatment. We sought to evaluate longitudinal neurocognitive functioning in male versus female children treated for posterior fossa brain tumors. Fifty-one female and 63 male survivors of posterior fossa tumors completed neuropsychological testing at 2 timepoints. We included patients treated with surgical resection, chemotherapy, and radiation therapy. Multilevel mixed modeling was used to predict IQ score as a function of patient sex following treatment (~2 or ~4 years post treatment). Effect sizes were used as a measure of clinical significance. Multilevel models resulted in a significant sex by time interaction (F = 6.69, P = 0.011). Females’ cognitive scores were considerably higher compared with males at 4 years posttreatment. Females demonstrated an average improvement of 7.61 standard score IQ points compared with a decline of 2.97 points for males at 4 years follow-up. Effect sizes for female IQ compared with male IQ at 4 years posttreatment were between 0.8 and 0.9. Trajectories of neurocognitive functioning following posterior fossa tumor treatment differed between female and male children. Sexual dimorphism in radiation late effects may alter treatment decisions in children. Research into sex-specific neuroprotective mechanisms underlying neurocognitive development following pediatric brain tumor treatments is warranted.